Insulin Glargine in the Treatment of Type 1 and Type 2 Diabetes

References

• BahrMKolterTSeipkeGGrowth promoting and metabolic activity of the human insulin analogue [GlyA21, ArgB31, ArgB32] insulin (HOE 901) in muscle cellsEur J Pharmacol1997320259659059862
   PubMed Web of Science ®Google Scholar
• BertiLKellererMBossenmaierBThe long acting human insulin analog HOE 901: characteristics of insulin signalling in comparison to Asp(B10) and regular insulinHorm Metab Res19983012399566852
   PubMed Web of Science ®Google Scholar
• BohannonNJVOptimizing insulin regimens in type 1 diabetes. How to help patients get control of their life. Postgraduate MedicinePostgrad Med200311339424585412838803
   PubMed Web of Science ®Google Scholar
• BolliGBOwensDRInsulin glargineLancet2000356443510981882
   PubMed Web of Science ®Google Scholar
• CampbellRKWhiteJRJrInsulin therapy in type 2 diabetesJ Am Pharm Assoc (Wash)2002426021112150359
   PubMedGoogle Scholar
• CiaraldiTPCarterLSeipkeGEffects of the long-acting insulin analog insulin glargine on cultured human skeletal muscle cells: comparisons to insulin and IGF-IJ Clin Endocrinol Metab20018658384711739448
   PubMed Web of Science ®Google Scholar
• CryerPEHypoglycemia is the limiting factor in the management of diabetesDiabetes Metab Res Rev19991542610398545
   PubMed Web of Science ®Google Scholar
• DaviesMStormsFShutlerSImprovement of glycemic control in subjects with poorly controlled type 2 diabetes: comparison of two treatment algorithms using insulin glargineDiabetes Care2005281288
   Web of Science ®Google Scholar
• [DCCT] DCCT Research GroupThe effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research GroupN Engl J Med1993329977868366922
   PubMed Web of Science ®Google Scholar
• [DCCT/EDIC] DCCT/EDIC Research GroupRetinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research GroupN Engl J Med2000342381910666428
   PubMedGoogle Scholar
• DevlinJTHothersallLWilkisJLUse of insulin glargine during pregnancy in a type 1 diabetic womanDiabetes Care2002251095612032121
   PubMed Web of Science ®Google Scholar
• Di CianniGVolpeLLencioniCUse of insulin glargine during the first weeks of pregnancy in five type 1 diabetic womenDiabetes Care200528982315793214
   PubMed Web of Science ®Google Scholar
• DixonANBainSCNausea and vomiting due to insulin glargine in patient with type 1 diabetes mellitusBMJ200533045515731143
   PubMed Web of Science ®Google Scholar
• DunnCJPloskerGLKeatingGMInsulin glargine: an updated review of its use in the management of diabetes mellitusDrugs20036317437812904090
   PubMed Web of Science ®Google Scholar
• FeherMBaileyCReclassifying insulinsBr J Diabetes Vasc Dis200413942
   Google Scholar
• GallenIWCarterCProspective audit of the introduction of insulin glargine (lantus) into clinical practice in type 1 diabetic patientsDiabetes Care2003263352314633830
   PubMed Web of Science ®Google Scholar
• GargSKPaulJMKarstenJIReduced severe hypoglycemia with insulin glargine in intensively treated adults with type 1 diabetesDiabetes Technol Ther200465899515628812
   PubMedGoogle Scholar
• GilliesPSFiggittDPLambHMInsulin glargineDrugs2000592536010730548
   PubMed Web of Science ®Google Scholar
• HeinemannLLinkeschovaRRaveKTime-action profile of the long-acting insulin analog insulin glargine (HOE901) in comparison with those of NPH insulin and placeboDiabetes Care200023644910834424
   PubMed Web of Science ®Google Scholar
• HeinemannLRichterBClinical pharmacology of human insulinDiabetes Care199316Suppl 3901008299482
   PubMedGoogle Scholar
• HershonKSBlevinsTCOnce-daily insulin glargine compared with twice-daily NPH insulin in patients with type 1 diabetesEndocr Pract200410101715251616
   PubMedGoogle Scholar
• HirschIBIntensive treatment of type 1 diabetesMed Clin North Am1998826897199706117
   PubMed Web of Science ®Google Scholar
• HolsteinAPlaschkeAEgbertsEHUse of insulin glargine during embryo-genesis in a pregnant woman with Type 1 diabetesDiabet Med2003207798012925063
   PubMed Web of Science ®Google Scholar
• HomePDBoultonAJMJimenezJon behalf of the Worldwide Initiative for Diabetes Education (WorldWIDE)Issues relating to the early or earlier use of insulin in type 2 diabetesPract Diab Int2003206371
   Google Scholar
• JehlePMMichelerCJehleDRInadequate suspension of neutral protamine Hagendorn (NPH) insulin in pensLancet19993541604710560676
   PubMed Web of Science ®Google Scholar
• KudvaYCBasuAJenkinsGDRandomized controlled clinical trial of glargine versus ultralente insulin in the treatment of type 1 diabetesDiabetes Care200528101415616226
   PubMed Web of Science ®Google Scholar
• KurtzhalsPSchafferLSorensenACorrelations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical useDiabetes200049999100510866053
   PubMed Web of Science ®Google Scholar
• LANTUS®Insulin glargine (rDNA origin) injection. Prescribing Information2004Kansas City, MO 64137, USAAventis Pharmaceuticals, Inc
   Google Scholar
• LeporeMPampanelliSFanelliCPharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lisproDiabetes2000492142811118018
   PubMed Web of Science ®Google Scholar
• NathanDMLachinJClearyPIntensive diabetes therapy and carotid intima-media thickness in type 1 diabetes mellitusN Engl J Med2003348229430312788993
   PubMed Web of Science ®Google Scholar
• NathanDMClearyPABacklundJYIntensive diabetes treatment and cardiovascular disease in patients with type 1 diabetesN Engl J Med200535326435316371630
   PubMed Web of Science ®Google Scholar
• NICEAppraisal consultation document: The clinical effectiveness and cost effectiveness of long-acting insulin analogues for diabetes [online]2002 Accessed October 2005. URL: http://www.nice.org.uk/article.asp?a=35497
   Google Scholar
• OwensDRCoatesPALuzioSDPharmacokinetics of 125Ilabeled insulin glargine (HOE 901) in healthy men: comparison with NPH insulin and the influence of different subcutaneous injection sitesDiabetes Care2000238131910841002
   PubMed Web of Science ®Google Scholar
• PieberTREugene-JolchineIDerobertEEfficacy and safety of HOE 901 versus NPH insulin in patients with type 1 diabetes. The European Study Group of HOE 901 in type 1 diabetesDiabetes Care2000231576210868824
   PubMed Web of Science ®Google Scholar
• PutzDKabadiUMInsulin glargine in continuous enteric tube feedingDiabetes Care20022518899012351503
   PubMed Web of Science ®Google Scholar
• RaskinPKlaffLBergenstalRA 16-week comparison of the novel insulin analog insulin glargine (HOE 901) and NPH human insulin used with insulin lispro in patients with type 1 diabetesDiabetes Care20002316667111092290
   PubMed Web of Science ®Google Scholar
• RatnerREHirschIBNeifingJLLess hypoglycemia with insulin glargine in intensive insulin therapy for type 1 diabetes U.S Study Group of Insulin Glargine in Type 1 DiabetesDiabetes Care2000236394310834423
   PubMed Web of Science ®Google Scholar
• RiddleMCRosenstockJGerichJThe treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patientsDiabetes Care2003263080614578243
   PubMed Web of Science ®Google Scholar
• RosenstockJDaileyGMassi-BenedettiMReduced hypoglycemia risk with insulin glargine: a meta-analysis comparing insulin glargine with human NPH insulin in type 2 diabetesDiabetes Care200528950515793205
   PubMed Web of Science ®Google Scholar
• RosenstockJParkGZimmermanJBasal insulin glargine (HOE 901) versus NPH insulin in patients with type 1 diabetes on multiple daily insulin regimens. US Insulin Glargine (HOE 901) Type 1 Diabetes Investigator GroupDiabetes Care20002311374210937511
   PubMed Web of Science ®Google Scholar
• RosenstockJSchwartzSLClarkCMJrBasal insulin therapy in type 2 diabetes: 28-week comparison of insulin glargine (HOE 901) and NPH insulinDiabetes Care200124631611315821
   PubMed Web of Science ®Google Scholar
• RosskampRHParkGLong-acting insulin analogsDiabetes Care199222Suppl 2B1091310097910
   PubMedGoogle Scholar
• SchoberESchoenleEVan DykJComparative trial between insulin glargine and NPH insulin in children and adolescents with type 1 diabetesDiabetes Care2001242005611679478
   PubMed Web of Science ®Google Scholar
• [UKPDS] UKPDS Study GroupUnited Kingdom Prospective Diabetes Study (UKPDS). 13: Relative efficacy of randomly allocated diet, sulphonylurea, insulin, or metformin in patients with newly diagnosed non-insulin dependent diabetes followed for three yearsBMJ1995a310838
   PubMedGoogle Scholar
• [UKPDS] UKPDS Study GroupUK prospective diabetes study 16. Overview of 6 years' therapy of type II diabetes: a progressive disease. UK Prospective Diabetes Study (UKPDS) GroupDiabetes1995b44124958
   PubMed Web of Science ®Google Scholar
• [UKPDS] UKPDS Study GroupIntensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) GroupLancet1998a35283753
   PubMed Web of Science ®Google Scholar
• [UKPDS] UKPDS Study GroupEffect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) GroupLancet1998b35285465
   PubMed Web of Science ®Google Scholar
• WallaceTMMatthewsDRPoor glycemic control in type 2 diabetes: a conspiracy of disease, suboptimal therapy and attitudeQJM2000933697410873187
   PubMed Web of Science ®Google Scholar
• WitthausEStewartJBradleyCTreatment satisfaction and psychological well-being with insulin glargine compared with NPH in patients with Type 1 diabetesDiabet Med2001186192511553198
   PubMed Web of Science ®Google Scholar
• WrightABurdenACPaiseyRSulfonylurea inadequacy: efficacy of addition of insulin over 6 years in patients with type 2 diabetes in the UK Prospective Diabetes Study (UKPDS 57)Diabetes Care200225330611815505
   PubMed Web of Science ®Google Scholar
• Yki-JarvinenHDresslerAZiemenMLess nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes. HOE 901/3002 Study GroupDiabetes Care2000231130610937510
   PubMed Web of Science ®Google Scholar
• ZinmanBRossSCamposRVEffectiveness of human ultralente versus NPH insulin in providing basal insulin replacement for an insulin lispro multiple daily injection regimen. A double-blind randomized prospective trial. The Canadian Lispro Study GroupDiabetes Care199922603810189539
   PubMed Web of Science ®Google Scholar